All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
GFB 111
Known as:
GFB-111
, GFB111
Â
Â
National Institutes of Health
Topic mentions per year
Topic mentions per year
2000-2000
0
2
4
6
2000
2000
Related topics
Related topics
1 relation
Broader (1)
Cyclic Peptides
Related mentions per year
Related mentions per year
1955-2018
1960
1980
2000
2020
GFB 111
Cyclic Peptides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice
Michelle A. Blaskovich
,
Qing Lin
,
+5 authors
Saïd M. Sebti
Nature Biotechnology
2000
We have designed a molecule, GFB-111, that binds to platelet-derived growth factor (PDGF), prevents it from binding to its…Â
(More)
Is this relevant?
Review
2000
Review
2000
Design of growth factor antagonists with antiangiogenic and antitumor properties
Saïd M. Sebti
,
Andrew D. Hamilton
Oncogene
2000
This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design…Â
(More)
Is this relevant?
2000
2000
Protein identification at nanomolar concentration
Judy Jamison
Nature Biotechnology
2000
promising area involves the design of smallmolecule inhibitors of growth factors active in malignancies. PDGF and its receptors…Â
(More)
Is this relevant?
2000
2000
A FACS screen for improving enzymes
Natalie DeWitt
Nature Biotechnology
2000
promising area involves the design of smallmolecule inhibitors of growth factors active in malignancies. PDGF and its receptors…Â
(More)
Is this relevant?
2000
2000
Synthetic transcriptional activators
Meeghan Sinclair
Nature Biotechnology
2000
promising area involves the design of smallmolecule inhibitors of growth factors active in malignancies. PDGF and its receptors…Â
(More)
Is this relevant?
2000
2000
A small-molecule PDGF inhibitor
Judy Jamison
Nature Biotechnology
2000
promising area involves the design of smallmolecule inhibitors of growth factors active in malignancies. PDGF and its receptors…Â
(More)
Is this relevant?